AMCP joins other stakeholders to oppose language in S. 2700 that would exempt biological medicines from the requirement to adhere to USP public standards for quality.
AMCP joins other stakeholders to oppose language in S. 2700 that would exempt biological medicines from the requirement to adhere to USP public standards for quality.